Interactions in Neurodegenerative Disorders
Alpha-Synuclein is a 14-19 kDa phosphoprotein primarily localized in the presynaptic terminals of mature neurons, where it is involved in synaptic function and plasticity.
Alpha-Synuclein was the first missense mutation identified as a cause of familial Parkinson’s disease.
Aggregated and hyper-phosphorylated forms of Alpha-Synuclein are the major components of Lewy bodies.
Alpha-Synuclein is involved in regulation of the dopaminergic pathway.
Alpha-Synuclein reduces neuronal responsiveness to various apoptotic stimuli, leading to decreased caspase-3 activation.
Alpha-Synuclein intermediate oligomers/protofibrils are thought to be the major neurotoxic species.
Alpha-Synuclein is a target for the treatment of Parkinson’s disease; a humanized monoclonal anti-Alpha-Synuclein (PRX002) is currently under Phase 1 trails.
Alpha-Synucleinopathies (protein?aggregates in neurons, nerve fibers, and glial cells)
Dementia (Lewy body)
Multiple system atrophy (Alpha-Synuclein?protein prions)
|10842-1-AP||Rabbit polyclonal||ELISA, WB, IHC, IF|
|View the Alpha-Synuclein product page here|
Immunofluorescence analysis of SH-SY5Y cells (human neuroblastoma) labeling Alpha-Synuclein with 10842-1-AP Proteintech antibody at a dilution of 1:25. Alexa Fluor 488-congugated AffiniPure Goat Anti-Rabbit IgG (H+L) was used as the secondary antibody and DAPI was used as the nuclear counterstain.
|22524-1-AP||6531||DAT||ELISA, IHC, WB, IP|
|18355-1-AP||5337||PLD1||ELISA, WB, IF, IP|
|14060-1-AP||5071||PARK2||ELISA, WB, IF|